Newronika Secures €13.6 Million Funding to Enhance Innovative DBS Solution
On February 13, 2025, Newronika, a pioneering entity in the realm of advanced deep brain stimulation (DBS), announced the successful conclusion of its Series B funding round, securing an impressive €13.6 million. The funding was predominantly led by Fondazione ENEA Tech e Biomedical, along with support from existing investors like Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. This substantial financial influx will be pivotal for Newronika as it endeavors to broaden the clinical validation and commercialization phases of its proprietary adaptive DBS system. This innovative platform is meticulously designed to provide precision therapy, enhancing symptom relief while minimizing side effects for patients suffering from Parkinson's disease.
With this fresh capital, Newronika aims to bolster its product pipeline, attract premier talent, and forge strategic partnerships, all of which will fortify its position at the intersection of medical device engineering and neuroscience. The company’s recent milestones, including a grant from The Michael J. Fox Foundation and IDE approval, underscore its mission to transform neuromodulation practices. Newronika is at the helm of a significant paradigm shift in the personalization of brain stimulation, demonstrating a firm commitment to advancing healthcare solutions tailored to individual patient needs.
Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika, expressed excitement over the unwavering support from both new and existing investors. He stated, "This Series B funding not only reaffirms our dedication to innovating the deep brain stimulation landscape but also propels us towards realizing the potential of integrating real-time neural data and machine learning into our DBS systems. Our objective is to create truly personalized therapies that exceed current market offerings."
Maria Cristina Porta, the General Manager of ENEA Tech e Biomedical, echoed this sentiment, remarking on the tremendous opportunities to transform the global treatment landscape for movement disorders through Newronika’s adaptive DBS platform. She emphasized ENEA’s commitment to supporting groundbreaking medical technologies that address urgent health needs within society.
Furthermore, Davide Turco, CEO of Indaco, voiced confidence in the impact of Newronika's adaptive DBS system on improving the quality of life for numerous Parkinson's patients. The successful Series B financing reflects Newronika's strategic vision and solidifies its commitment to redefine DBS technology in ways that directly benefit patients.
In summary, Newronika is revolutionizing the field of deep brain stimulation through its adaptive approach, utilizing real-time patient data to enhance therapeutic outcomes. Headquartered in Milan, Italy, the company is set on a relentless path to redefine possibilities in neuromodulation. With certifications like the CE Mark and an Investigational Device Exemption from the FDA, Newronika stands poised to lead the charge in next-generation therapies for neurological disorders. For further details and updates, visitors can explore Newronika's official website or follow the company on LinkedIn.
With this fresh capital, Newronika aims to bolster its product pipeline, attract premier talent, and forge strategic partnerships, all of which will fortify its position at the intersection of medical device engineering and neuroscience. The company’s recent milestones, including a grant from The Michael J. Fox Foundation and IDE approval, underscore its mission to transform neuromodulation practices. Newronika is at the helm of a significant paradigm shift in the personalization of brain stimulation, demonstrating a firm commitment to advancing healthcare solutions tailored to individual patient needs.
Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika, expressed excitement over the unwavering support from both new and existing investors. He stated, "This Series B funding not only reaffirms our dedication to innovating the deep brain stimulation landscape but also propels us towards realizing the potential of integrating real-time neural data and machine learning into our DBS systems. Our objective is to create truly personalized therapies that exceed current market offerings."
Maria Cristina Porta, the General Manager of ENEA Tech e Biomedical, echoed this sentiment, remarking on the tremendous opportunities to transform the global treatment landscape for movement disorders through Newronika’s adaptive DBS platform. She emphasized ENEA’s commitment to supporting groundbreaking medical technologies that address urgent health needs within society.
Furthermore, Davide Turco, CEO of Indaco, voiced confidence in the impact of Newronika's adaptive DBS system on improving the quality of life for numerous Parkinson's patients. The successful Series B financing reflects Newronika's strategic vision and solidifies its commitment to redefine DBS technology in ways that directly benefit patients.
In summary, Newronika is revolutionizing the field of deep brain stimulation through its adaptive approach, utilizing real-time patient data to enhance therapeutic outcomes. Headquartered in Milan, Italy, the company is set on a relentless path to redefine possibilities in neuromodulation. With certifications like the CE Mark and an Investigational Device Exemption from the FDA, Newronika stands poised to lead the charge in next-generation therapies for neurological disorders. For further details and updates, visitors can explore Newronika's official website or follow the company on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.